SCHEMBL9923266

SCHEMBL9923266

CNc1cccc(C2=NN(c3ccc(NC(=O)NS(=O)(=O)c4ccc(C)s4)cc3)C(=O)C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.40
TP53 P04637 2/20 0.38
P2RY12 Q9H244 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRK5 P34947 1/20 0.36
CDK8 P49336 1/20 0.36
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NAMPT P43490 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 1/20 0.33
APP P05067 1/20 0.33
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12161731 0.91 P2RY12 (0.47) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL13182770 0.90 P2RY12 (0.38) TP53P2RY12MEN1KMT2ALMNA
SCHEMBL9922239 0.90 TP53 (0.35) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL14228355 0.89 MEN1 (0.43) MEN1KMT2ALMNASMN1; SMN2GRK5
SCHEMBL9923267 0.89 CNR1 (0.38) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL9923270 0.89 TP53 (0.39) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL9923269 0.88 CNR1 (0.37) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL14113622 0.88 CNR1 (0.41) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL9923268 0.88 TP53 (0.36) CNR1TP53P2RY12MEN1KMT2A
SCHEMBL9922235 0.85 TP53 (0.42) CNR1TP53P2RY12MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 CNR1 264/4885TP53 4462/4885P2RY12 19/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 CNR1 253/4885TP53 4435/4885P2RY12 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.